Pfizer Receives Initial Communication from U.S. Patent and Trademark Office Regarding Lipitor Basic Patent
NEW YORK -- Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued its first communication in the reexamination of the â€˜893 basic patent for Lipitor, initially rejecting the patentâ€™s claims. This initial action, which is how the Office raises its issues with the patentee, will now be followed by the companyâ€™s response, in which Pfizer will address those issues raised by the examiner. As the company previously indicated, an initial rejection is not unusual in reexamination proceedings.
â€œWe will respond as appropriate to the issues raised by the examiner, and believe we have compelling arguments in our favor,â€ said Pfizer General Counsel Allen Waxman. â€œWe continue to believe that the basic patent was properly granted and will be upheld on reexamination. This initial action, which was not unexpected, does not change that.â€
The patent remains valid and enforceable throughout the re-examination proceeding, which could take as long as a few years.
More information can be found at www.pfizer.com.